

CURRENT REPORT 39/2020

October 14, 2020

Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020

The Management Board of Ryvu Therapeutics S.A. with its registered office in Cracow ("Company") hereby announces that the abstract regarding its STING agonists program has been accepted for presentation at the upcoming Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020) which will take place November 9-14, 2020.

The abstract will be presented during the virtual poster session on November 11-14 from 9.00 AM till 5.00 PM.

Title: *Development of improved small molecule STING agonists suitable for systemic administration*

Abstract ID: 414

To view the abstract, please visit: <https://www.sitcancer.org/2020/abstracts/abstract-information>.

SITC 2020 provides a multidisciplinary educational and interactive environment focused on improving cancer patient outcomes by incorporating strategies based on basic and applied cancer immunotherapy.

Legal basis: Article 17.1 of Market Abuse Regulation

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board